https://www.selleckchem.com/products/mln2480.html
Cox regression analysis demonstrated that only patients with ECOG PS ≤1 or no liver metastases had longer PFS and OS. Grade 3 treatment-related adverse events were reported in 14% of the patients, but no life-threatening adverse events were reported. Conclusion Anlotinib was well tolerated and effective in patients with advanced NSCLC in real-world conditions. Patients with ECOG PS ≤1 or no liver metastases have longer PFS and OS.Introduction The oncogenic role of lncRNA LUADT1 has been investigated only in lung cancer. This study aimed
Like
Comment
Share
